Whether Alnylam's Guidance Can Justify Analysts Finally Turning Bullish After Years of Misses

Alnylam Pharmaceuticals (ALNY) reports second-quarter fiscal 2026 earnings tomorrow, July 30, before the market opens, with analysts expecting $1.44 per share — a dramatic turnaround from the $0.52 loss posted in the same quarter last year. The central question is whether the RNAi therapeutics pioneer can sustain the momentum from its recent string of earnings beats and validate the aggressive upward revisions to full-year estimates. With the stock trading well below its 200-day moving average and technical signals flashing caution, execution against elevated expectations will be critical.

Part 1: Earnings Preview

Alnylam Pharmaceuticals is a leading global biopharmaceutical company pioneering RNA interference (RNAi) therapeutics, with six approved medicines including ONPATTRO, AMVUTTRA, and GIVLAARI targeting rare genetic diseases. The company has expanded its commercial footprint to more than 70 countries while advancing a robust pipeline spanning metabolic, cardiovascular, and neurological disorders.

Alnylam reports Q2 FY2026 results on July 30, 2026, before the market opens. Analysts expect $1.44 per share, based on 8 estimates ranging from $1.00 to $1.86. The most recently reported quarter (Q1 FY2026) delivered $1.51 per share, crushing the $0.91 consensus by 66%. Year-over-year, the Q2 estimate represents a +376.92% surge from the $0.52 loss reported in Q2 FY2025, reflecting the company's transition to sustained profitability.

Three key themes define this earnings story:

Commercial Execution and Revenue Growth: Investors will scrutinize whether Alnylam can deliver on revenue expectations after missing consensus in Q4 2025 ($1.10B actual vs. $1.16B estimate). The company's ability to drive uptake across its approved product portfolio — particularly newer launches like Qfitlia for hemophilia — will be critical to validating the aggressive full-year estimate of $7.35 per share (up from a prior $2.33).

Pipeline Progress and Regulatory Milestones: With multiple Phase 3 candidates including nucresiran for ATTR amyloidosis, zilebesiran for hypertension, and cemdisiran for multiple indications, any updates on trial readouts or regulatory submissions could significantly impact the growth narrative. The company's expansion into larger patient populations beyond rare diseases represents a major inflection point.

Profitability Trajectory: After posting four consecutive profitable quarters, investors want confirmation that Alnylam's operating leverage is sustainable. The company's ability to balance R&D investment in its expansive pipeline with margin expansion will determine whether the current $7.35 full-year estimate — and the $10.32 projection for FY2027 — are achievable.

Analyst commentary ahead of the release emphasizes cautious optimism. While the consensus has been revised sharply higher throughout 2026, some analysts note that execution risk remains elevated given the company's history of volatility. The Q4 2025 miss on both EPS and revenue serves as a reminder that even strong underlying fundamentals can be overshadowed by near-term execution challenges.

Part 2: Historical Earnings Performance

Alnylam has demonstrated strong recent momentum, beating consensus EPS estimates in three of the last four quarters. The most recent quarter (Q1 FY2026) delivered a +65.93% surprise ($1.51 actual vs. $0.91 estimate), following an even more dramatic +300.00% beat in Q3 FY2025 ($1.84 vs. $0.46). The Q2 FY2025 result showed a +10.34% beat ($-0.52 vs. $-0.58 estimate), while Q4 FY2025 posted a modest +9.33% beat ($0.82 vs. $0.75).

The pattern reveals a company that has consistently exceeded expectations since mid-2025, with surprise magnitudes accelerating dramatically in the second half of the year. The Q3 2025 blowout quarter marked a clear inflection point, suggesting operational improvements and commercial traction that have persisted into 2026. However, the absolute EPS figures show significant quarter-to-quarter volatility — ranging from losses to substantial profits — reflecting the lumpy nature of biotech earnings driven by milestone payments, R&D timing, and product launch dynamics.

The consistency of beats over the past year has likely contributed to the aggressive upward revisions in forward estimates, with analysts now modeling sustained profitability rather than the intermittent losses that characterized earlier periods. This track record sets a high bar for tomorrow's release, as investors will expect Alnylam to continue outperforming rather than simply meeting the elevated consensus.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Alnylam typically reports before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.

Historical price behavior shows significant volatility around Alnylam earnings, with an average absolute Day 0 move of 6.38% and Day 0 range of 8.14%. The most dramatic reactions occurred in Q2 FY2025 (July 2025), when the stock surged 15.43% on earnings day, and Q3 FY2025 (October 2025), when it dropped 6.65%. The most recent Q1 FY2026 report (April 2026) produced a more modest 2.76% gain despite the significant earnings beat.

Day +1 follow-through has been more muted, averaging 2.38% with a 4.69% range, suggesting most of the price discovery happens in the immediate reaction session. The pattern indicates that positive surprises can drive substantial upside — the July 2025 earnings triggered a two-day rally totaling over 17% — while disappointments tend to be punished swiftly but with less extreme downside.

Investors should anticipate meaningful volatility tomorrow, particularly given the elevated expectations and the stock's recent underperformance relative to longer-term moving averages. The historical data suggests a potential swing of 6-8% is well within normal parameters for ALNY earnings reactions.

Part 2.2: Options Market Expected Move

The options market is pricing an 9.74% expected move for the August expiration cycle, which is notably higher than the 6.38% average historical Day 0 move. This suggests options traders are anticipating above-average volatility for this release, possibly reflecting uncertainty around whether the company can sustain its recent momentum or concerns about execution given the aggressive estimate revisions.

Part 3: What Analysts Are Saying

Analyst sentiment on Alnylam remains strongly bullish, with the consensus rating at 4.37 out of 5.0 (between Buy and Strong Buy). The current breakdown shows 17 Strong Buys, 3 Moderate Buys, and 7 Holds, with zero sell ratings. This represents improved sentiment compared to one month ago, when the rating stood at 4.34 with 18 Strong Buys and 8 Holds.

The average price target of $437.62 implies 52.7% upside from the current price of $286.62, reflecting substantial conviction in the company's long-term growth trajectory. Target estimates span a wide range from $285.00 to $566.00, indicating divergent views on the pace and magnitude of Alnylam's commercial ramp and pipeline value. The high-end target suggests some analysts see potential for the stock to nearly double from current levels.

The recent improvement in sentiment — with one analyst upgrading from Hold while maintaining the Strong Buy count near record levels — suggests the analyst community is gaining confidence in Alnylam's ability to execute on its commercial and pipeline opportunities. However, the presence of 7 Hold ratings indicates some caution remains, likely reflecting valuation considerations or execution risk around the aggressive earnings growth expectations embedded in current estimates.

Part 4: Technical Picture

The Barchart Technical Opinion shows a 100% Sell signal, intensifying from 88% Sell both one week and one month ago. This deteriorating technical picture reflects sustained downward pressure as the stock has failed to regain momentum.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates near-term momentum is decisively negative heading into earnings
• Medium-term (100% Sell): Bearish reading confirms weakness across the intermediate timeframe with no signs of stabilization
• Long-term (100% Sell): Sell signal across all timeframes reflects broad-based technical deterioration

Trend Characteristics: Average strength with average direction suggests the downtrend is established but not accelerating dramatically, indicating a grinding decline rather than panic selling.

The stock is trading at $286.62, positioned above both the 5-day ($278.79) and 10-day ($275.56) moving averages, but below all longer-term averages including the 20-day ($289.41), 50-day ($291.52), 100-day ($302.19), and 200-day ($351.86). This configuration shows a stock in a clear downtrend that has bounced modestly in recent days but remains well below key resistance levels.

The 200-day moving average at $351.86 represents a critical resistance level 22.8% above the current price, while the 50-day at $291.52 provides nearer-term overhead resistance just 1.7% higher. Support appears to be forming around the recent lows near $275, which aligns with the 10-day moving average. The overall technical setup is cautionary heading into earnings — while the stock has stabilized after recent weakness, it lacks the momentum typically associated with bullish breakouts. A strong earnings beat and positive guidance would need to be substantial to overcome the technical headwinds and trigger a sustained reversal above the 50-day and 200-day moving averages.